23,247 results match your criteria Chronic Myelogenous Leukemia


Identification of the Direct Substrates of the ABL Kinase via Kinase Assay Linked Phosphoproteomics with Multiple Drug Treatments.

J Proteome Res 2019 Mar 14. Epub 2019 Mar 14.

Ableson tyrosine kinase (ABL) plays an essential role in cell differentiation, division, adhesion, and stress response. However, the mutant fusion BCR-ABL has constitutive kinase activity that causes chronic myelogenous leukemia (CML). Small molecule tyrosine kinase inhibitors (TKIs) such as imatinib revolutionized the treatment of CML and other cancers, but acquired resistance to these inhibitors, even second-generation TKIs, is rising. Read More

View Article

Download full-text PDF

Source
http://pubs.acs.org/doi/10.1021/acs.jproteome.8b00942
Publisher Site
http://dx.doi.org/10.1021/acs.jproteome.8b00942DOI Listing
March 2019
1 Read

Iridocorneal leukemic infiltrate in chronic myelogenous leukemia.

J Fr Ophtalmol 2019 Mar 6. Epub 2019 Mar 6.

Stanford University School of Medicine, Palo Alto, CA, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jfo.2018.05.021DOI Listing

Microenvironment tailors nTreg structure and function.

Proc Natl Acad Sci U S A 2019 Mar 7. Epub 2019 Mar 7.

Laboratory of Oncodermatology, Immunology, and Cutaneous Stem Cells, INSERM U976, 75010 Paris, France.

Natural regulatory T cells (nTregs) ensure the control of self-tolerance and are currently used in clinical trials to alleviate autoimmune diseases and graft-versus-host disease after hematopoietic stem cell transfer. Based on CD39/CD26 markers, blood nTreg analysis revealed the presence of five different cell subsets, each representing a distinct stage of maturation. Ex vivo added microenvironmental factors, including IL-2, TGFβ, and PGE2, direct the conversion from naive precursor to immature memory and finally from immature to mature memory cells, the latest being a no-return stage. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1812471116DOI Listing
March 2019
7 Reads

Dasatinib-induced nephrotic syndrome in a patient with chronic myelogenous leukemia: a case report.

BMC Nephrol 2019 Mar 7;20(1):87. Epub 2019 Mar 7.

Dialysis Division, University of Miyazaki Hospital, Miyazaki, Japan.

Background: Dasatinib is a second-generation tyrosine kinase inhibitor that is indicated for the treatment of patients with chronic myeloid leukemia. Here, we report the case of a man with nephrotic syndrome that was caused by dasatinib.

Case Presentation: A 40-year-old man with chronic myeloid leukemia was referred to our hospital because of proteinuria 1 month after dasatinib therapy was introduced. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12882-019-1273-6DOI Listing
March 2019
1 Read

[Co-occurrence of t(8;21)(q22;q22) and t(9;22)(q34;q11) in a case with chronic myelogenous leukemia].

Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2019 Mar;36(3):253-256

Department of Pathology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Tianjin 300020, China. ru

Objective: To delineate laboratory and clinical characteristics of a case with chronic myelogenous leukemia (CML) and co-occurrence of t(9;22)(q34;q11) and t(8;21)(q22;q22).

Methods: The patient was subjected to cytogenetic, molecular, morphological and immunophenotypic analyses.

Results: Cytogenetic analysis revealed presence of t(8;21)(q22;q22) in addition to t(9;22)(q34;q11) in the patient. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.issn.1003-9406.2019.03.015DOI Listing
March 2019
1 Read

Development of a Potent Protein Degrader against Oncogenic BCR-ABL Protein.

Chem Pharm Bull (Tokyo) 2019 ;67(3):165-172

Divisions of Molecular Target and Gene Therapy Products, National Institute of Health Sciences.

Chromosomal translocation occurs in some cancer cells, resulting in the expression of aberrant oncogenic fusion proteins that include BCR-ABL in chronic myelogenous leukemia (CML). Inhibitors of ABL tyrosine kinase, such as imatinib and dasatinib, exhibit remarkable therapeutic effects, although emergence of drug resistance hampers the therapy during long-term treatment. An alternative approach to treat CML is to downregulate expression of the BCR-ABL protein. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1248/cpb.c18-00703DOI Listing
January 2019
1 Read

Discovery of the Oncogenic Parp1, a Target of bcr-abl and a Potential Therapeutic, in mir-181a/PPFIA1 Signaling Pathway.

Mol Ther Nucleic Acids 2019 Feb 8;16:1-14. Epub 2019 Feb 8.

Department of Biochemistry and Molecular Biology, Medical College of Jinan University, Guangzhou 510632, China; Insititute of Chinese Integrative Medicine, Medical College of Jinan University, Guangzhou 510632, China; Engineering Technology Research Center of Drug Development for Small Nucleic Acid, Guangdong, China; Antisense Biopharmaceutical Technology Co., Ltd., Guangzhou, China. Electronic address:

miR-181a is downregulated in leukemia and affects its progression, drug resistance, and prognosis. However, the exact mechanism of its targets in leukemia, particularly in chronic myelogenous leukemia (CML), has not previously been established. Here, we use a multi-omics approach to demonstrate that protein tyrosine phosphatase, receptor type, f polypeptide, leukocyte common antigen (LAR) interacting protein (liprin), alpha 1 (PPFIA1) is a direct target for miR-181a in CML. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S21622531193001
Publisher Site
http://dx.doi.org/10.1016/j.omtn.2019.01.015DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6393709PMC
February 2019
2 Reads

Andrographolide and its potent derivative exhibit anticancer effects against imatinib-resistant chronic myeloid leukemia cells by downregulating the Bcr-Abl oncoprotein.

Biochem Pharmacol 2019 Feb 26;163:308-320. Epub 2019 Feb 26.

Institute of Traditional Medicine, National Yang-Ming University, Taipei 11221, Taiwan; Program in Molecular Medicine, National Yang-Ming University and Academia Sinica, Taipei 11221, Taiwan. Electronic address:

Chronic myelogenous leukemia (CML) is clinically treated with imatinib, which inhibits the kinase activity of the Bcr-Abl oncoprotein. However, imatinib resistance remains a common clinical issue. Andrographolide, the major compound of the medicinal plant Andrographis paniculata, was reported to exhibit anticancer activity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bcp.2019.02.028DOI Listing
February 2019
5 Reads

Network meta-analysis: a new analysis tool of the experimental evidence.

Minerva Med 2019 Apr;110(2):173-175

Department of Geriatrics, "Casa Sollievo della Sofferenza" Hospital, San Giovanni Rotondo, Foggia, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.23736/S0026-4806.18.05768-3DOI Listing
April 2019
2 Reads

Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice.

Haematologica 2019 Feb 28. Epub 2019 Feb 28.

Department of Clinical and Biological Sciences, University of Turin, Orbassano (TO), Italy.

It is judged safe to discontinue treatment with tyrosine kinase inhibitors for chronic myeloid leukemia in experimental trials on treatment free remission. We collected a total of 293 Italian patients with chronic phase chronic myeloid leukemia who discontinued tyrosine kinase inhibitors in deep molecular response. 72% of patients were on treatment with imatinib, 28% with second generation tyrosine kinase inhibitors at the time of discontinuation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.205054DOI Listing
February 2019
2 Reads

De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways.

Haematologica 2019 Feb 28. Epub 2019 Feb 28.

University of Milano - Bicocca, Italy;

Despite the advent of tyrosine kinase inhibitors, a proportion of chronic myeloid leukemia patients in chronic phase fails to respond to Imatinib or to second generation inhibitors and progress to blast crisis. Limited improvements in the understanding of the molecular mechanisms responsible for chronic myeloid leukemia transformation from chronic phase to the aggressive blast crisis were achieved until now. We present here a massive parallel sequencing analysis of 10 blast crisis samples and of the corresponding autologous chronic phase controls which reveals, for the first time, recurrent mutations affecting the ubiquitin-conjugating enzyme E2A gene (UBE2A, formerly RAD6A). Read More

View Article

Download full-text PDF

Source
http://www.haematologica.org/lookup/doi/10.3324/haematol.201
Publisher Site
http://dx.doi.org/10.3324/haematol.2017.179937DOI Listing
February 2019
4 Reads

Imatinib-induced irreversible interstitial lung disease: A case report.

Medicine (Baltimore) 2019 Feb;98(8):e14402

Department of Hematology.

Rationale: Imatinib mesylate (imatinib) is a classic tyrosine kinase inhibitor used to treat chronic myeloid leukemia. Although it is well tolerated by most patients and helps in the achievement of complete remission, a few rare imatinib-associated adverse effects such as pulmonary interstitial fibrosis have been reported. Because of its rareity, the clinical features of imatinib-induced interstitial lung disease (ILD) remain unclear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000014402DOI Listing
February 2019

Concurrent JAK2-Positive Myeloproliferative Disorder and Chronic Myelogenous Leukemia: A Novel Entity? A Case Report With Review of the Literature.

J Investig Med High Impact Case Rep 2019 Jan-Dec;7:2324709619832322

2 GV Montgomery VA Medical Center, Jackson, MS, USA.

JAK2 V617F mutation and BCR-ABL translocation have been considered to be mutually exclusive. However, many cases where both hits coexisted have been reported. We have personally managed a case too. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2324709619832322DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6393948PMC
February 2019
1 Read

Dasatinib Re-initiation after Post-stroke Thrombolysis Associated with Symptomatic Intracerebral Hemorrhage.

World Neurosurg 2019 Feb 21. Epub 2019 Feb 21.

Department of Neurology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK. Electronic address:

Background: Dasatinib, a tyrosine kinase inhibitor commonly used in treatment of acute lymphoblastic leukemia and chronic myelogenous leukemia (CML), is often associated with hemorrhagic complications. Safety of Dasatinib after thrombolytic therapy in acute ischemic stroke (AIS) is unknown.

Case Description: 63-year-old man with multiple vascular risk factors and CML (in molecular remission) on Dasatinib presented with signs and symptoms of right hemispheric stroke due to acute intracranial internal carotid artery occlusion that was treated with intravenous thrombolysis and mechanical thrombectomy resulting in near complete resolution of stroke symptoms. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S18788750193043
Publisher Site
http://dx.doi.org/10.1016/j.wneu.2019.02.026DOI Listing
February 2019
4 Reads

Dasatinib for chronic myelogenous leukemia improves skin symptoms of systemic sclerosis.

Int J Hematol 2019 Feb 20. Epub 2019 Feb 20.

Department of Hematology, Ome Municipal General Hospital, 4-16-5, Higashiome, Ome, Tokyo, Japan.

A 64-year-old man was diagnosed with limited cutaneous systemic sclerosis 5 years prior to this report. His sclerotic skin symptoms did not respond to oral low-dose prednisone (5-10 mg/day). Five years after the diagnosis, the patient presented with leukocytosis 3. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-019-02618-wDOI Listing
February 2019
1 Read

Tyrosine Kinase Inhibitor Associated Fibrothorax.

Am J Respir Crit Care Med 2019 Feb 20. Epub 2019 Feb 20.

The University of Texas Health Science Center at Houston, Internal Medicine-Division of Critical Care Medicine, Houston, Texas, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1164/rccm.201806-1155IMDOI Listing
February 2019
3 Reads

Pak1 gene functioned differentially in different BCR-ABL subtypes in leukemiagenesis and treatment response through STAT5 pathway.

Leuk Res 2019 Apr 24;79:6-16. Epub 2019 Jan 24.

Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, People's Republic of China. Electronic address:

The BCR-ABL fusion gene (BCR-ABL) has different subtypes such as p210 and p190 with p190 appear to lead to a worse prognosis. To explore the mechanism of difference in pathogenesis and prognosis in different BCR-ABL subtype-related leukemia, expression profile microarray analysis was conducted between p190 and p210 patients and verified by RT-PCR. The p21-activated kinase (PAK1) gene was chosen and regulation of the PAK1-STAT5 biological axis and its influence on proliferation and apoptosis in leukemia cells were also analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2019.01.012DOI Listing
April 2019
1 Read

Highly efficient Polyaniline-MoS hybrid nanostructures based biosensor for cancer biomarker detection.

Anal Chim Acta 2019 May 21;1055:26-35. Epub 2018 Dec 21.

CSIR-National Physical Laboratory, New Delhi, 110012, India. Electronic address:

In this work, polyaniline nanospindles have been synthesized using iron oxide as sacrificial template. These nanospindles were utilized for the fabrication of PANI-MoS nanoflower architectures via hydrothermal route. The electrostatic interaction between PANI and MoS improves the conductivity and provides more direct paths for charge transportation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.aca.2018.12.033DOI Listing
May 2019
3 Reads

[Research Progress of C-Myc in Chronic Myelogenous Leukemia --Review].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2019 Feb;27(1):297-300

Department of Hematology, The First People's Hospital of Huaian Affiliated to Nanjing Medical University, Huaian, 223300, Jiangsu Province, China.E-mail:

As a potential target for cancer treatment, the C-Myc high expresses abnormally in a variety of solid tumors and hematological malignancies in humans. In hematologic malignancies, the increasing expression of C-Myc is associated with poor prognosis of patients diffuse large B-cell lymphoma. However, some studies have shown that high expression of C-Myc might be one of the mechanisms of disease progression and abrupt change, therefore, it can promote the transformation of chronic myeloid leukemia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7534/j.issn.1009-2137.2019.01.049DOI Listing
February 2019
1 Read

Computed tomography-measured pulmonary artery to aorta ratio and EUTOS score for detecting dasatinib-induced pulmonary arterial hypertension.

Int J Cardiovasc Imaging 2019 Feb 4. Epub 2019 Feb 4.

Division of Cardiology, National Defense Medical College, 3-2 Namiki, Tokorozawa, 359-8513, Japan.

Background: Periodic echo-based screening to detect early stages of a rare complication of dasatinib, pulmonary arterial hypertension (PAH), is inefficient and weakens the potential benefit of dasatinib as a potent drug for chronic myelogenous leukemia (CML). This study aimed to identify the predisposing factors of DASA-PAH to stratify high-risk patients for dasatinib-induced PAH (DASA-PAH).

Methods: Sixty consecutive adult patients who received dasatinib were enrolled in this case-control study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10554-019-01548-2DOI Listing
February 2019
2 Reads

Hematopoietic Cell Transplantation for Paroxysmal Nocturnal Hemoglobinuria in the Age of Eculizumab.

Biol Blood Marrow Transplant 2019 Feb 1. Epub 2019 Feb 1.

Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; Division of Medical Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, Washington. Electronic address:

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired clonal hematopoietic cell disease characterized by the destruction of hematopoietic cells through activation of the complement system with manifestations that can be life-threatening including hemolysis, thrombosis, and marrow failure. Allogeneic hematopoietic cell transplantation (HCT) remains the sole cure for PNH, but eculizumab, a terminal complement inhibitor of C5, has been used to prevent complement-mediated hemolysis in patients with PNH since its approval by the Food and Drug Administration in 2007. We examined outcomes of HCT in patients with PNH to evaluate the effects of disease subtype, conditioning intensity, and eculizumab use either pre-HCT or post-HCT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.01.033DOI Listing
February 2019
2 Reads

The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors.

Cancer 2019 Feb 1. Epub 2019 Feb 1.

Department of Hematology, Local Social Health Authority (ASST) Spedali Civili Brescia, Brescia, Italy.

Background: Stopping tyrosine kinase inhibitor (TKI) treatment has become a realistic and safe objective for patients who have chronic myeloid leukemia (CML). Both a sustained deep molecular response (sDMR) and the lack of a molecular recurrence after TKI discontinuation are required to reach a durable treatment-free remission (TFR).

Methods: The potential predictive role of BCR-ABL transcripts in attaining an sDMR and a TFR was analyzed in a strictly consecutive, unselected series of 194 patients who were diagnosed and treated with TKIs at the authors' center. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cncr.31977
Publisher Site
http://dx.doi.org/10.1002/cncr.31977DOI Listing
February 2019
5 Reads

Modeling Episode-Based Payments for Cancer Using Commercial Claims Data.

J Manag Care Spec Pharm 2019 Feb;25(2):235-245

2 Novartis, East Hanover, New Jersey.

Background: Innovative health care reimbursement models are gaining attention as a way to move away from a payment system that rewards quantity of service over quality of care. One such alternative payment model is episode-based payment, such as the Oncology Care Model (OCM) being piloted by the Center for Medicare & Medicaid Innovation.

Objective: To adapt the OCM methodology to a commercially insured population to understand the challenges and potential implications of implementing an episode-based payment model in a commercial health plan. Read More

View Article

Download full-text PDF

Source
https://www.jmcp.org/doi/10.18553/jmcp.2019.25.2.235
Publisher Site
http://dx.doi.org/10.18553/jmcp.2019.25.2.235DOI Listing
February 2019
7 Reads

Thrombotic microangiopathy as a cause of cardiovascular toxicity from the BCR-ABL1 tyrosine kinase inhibitor ponatinib.

Blood 2019 Jan 28. Epub 2019 Jan 28.

Oregon National Primate Research Center, Oregon Health & Science University, Portland, OR, United States

The third generation tyrosine kinase inhibitor (TKI) ponatinib is effective against drug-resistant chronic myelogenous leukemia, but has been plagued by high rates of acute ischemic events. The pathophysiology responsible for these events is unknown. We hypothesized that ponatinib produces an endothelial angiopathy involving excessive endothelial-associated von Willebrand factor (VWF) and secondary platelet adhesion. Read More

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/lookup/doi/10.1182/blood-2018-10
Publisher Site
http://dx.doi.org/10.1182/blood-2018-10-881557DOI Listing
January 2019
6 Reads

A Novel Naphthoquinone-Coumarin Hybrid That Inhibits BCR-ABL1-STAT5 Oncogenic Pathway and Reduces Survival in Imatinib-Resistant Chronic Myelogenous Leukemia Cells.

Front Pharmacol 2018 9;9:1546. Epub 2019 Jan 9.

Laboratorio de Farmacología Molecular y Traslacional, Instituto Universitario de Investigaciones Biomédicas y Sanitarias, Universidad de Las Palmas de Gran Canaria, Las Palmas, Spain.

BCR-ABL1-STAT5 is an oncogenic signaling pathway in human chronic myelogenous leukemia (CML) and it represents a valid target for anti-CML drug design. Resistance to direct BCR-ABL1 inhibitors is a common clinical issue, so STAT5 inhibition has become an interesting alternative target. In this study, the effects of NPQ-C6, a novel naphtoquinone-coumarin conjugate, were evaluated on human CML-derived K562 cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fphar.2018.01546DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6334626PMC
January 2019
2 Reads

Renal dysfunction and anemia associated with long-term imatinib treatment in patients with chronic myelogenous leukemia.

Int J Hematol 2019 Mar 24;109(3):292-298. Epub 2019 Jan 24.

Division of Hematology, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.

Knowledge of the toxicity profile of long-term treatment with imatinib is limited. In the present study, we sought to evaluate renal function and hemoglobin levels during long-term imatinib treatment. Eighty-two patients with chronic myelogenous leukemia in chronic phase who had been on imatinib for over 5 years were retrospectively analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-019-02596-zDOI Listing
March 2019
10 Reads

αβ T Cell-Depleted Haploidentical Hematopoietic Stem Cell Transplantation without Antithymocyte Globulin in Children with Chemorefractory Acute Myelogenous Leukemia.

Biol Blood Marrow Transplant 2019 Jan 21. Epub 2019 Jan 21.

Department of Hematopoietic Stem Cell Transplantation, Dmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, and Immunology, Moscow, Russia. Electronic address:

We evaluated the outcome of αβ T cell-depleted haploidentical hematopoietic stem cell transplantation (HSCT) in a cohort of children with chemorefractory acute myelogenous leukemia (AML). Twenty-two patients with either primary refractory (n = 10) or relapsed refractory (n = 12) AML in active disease status received a transplant from haploidentical donors. The preparative regimen included cytoreduction with fludarabine and cytarabine and subsequent myeloablative conditioning with treosulfan and thiotepa. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10838791193007
Publisher Site
http://dx.doi.org/10.1016/j.bbmt.2019.01.023DOI Listing
January 2019
12 Reads

Anti-growth Effects of Imatinib and GNF5 via Regulation of Skp2 in Human Hepatocellular Carcinoma Cells.

J Cancer Prev 2018 Dec 30;23(4):170-175. Epub 2018 Dec 30.

Department of Dental Hygiene, College of Science and Technology, Kyungpook National University, Sangju, Korea.

Background: Human hepatocellular carcinoma (HCC) is a common liver tumor and the main cause of cancer-related death. Tyrosine kinase inhibitors, such as imatinib and GNF5 which were developed to treat chronic myelogenous leukemia, regulate the progression of various cancers. The aim of this study was to confirm the anti-tumor activity of tyrosine kinase inhibitors through regulation of S-phase kinase-associated protein 2 (Skp2), an important oncogenic factor in various cancer cells, in human hepatocarcinoma SK-HEP1 cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.15430/JCP.2018.23.4.170DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6330986PMC
December 2018
2 Reads

Approaches for generation of anti-leukemia specific T cells.

Cell Regen (Lond) 2018 Dec 2;7(2):40-44. Epub 2018 Nov 2.

Key Laboratory for Regenerative Medicine of Ministry of Education; Institute of Hematology, School of Medicine; Jinan University, Guangzhou, 510632, China.

As three decades ago, it was reported that adoptive T cell immunotherapy by infusion of autologous tumor infiltrating lymphocytes (TILs) mediated objective cancer regression in patients with metastatic melanoma. A new era of T cell immunotherapy arose since the improvement and clinical use of anti-CD19 chimeric antigen receptor T cells (CAR-T) for the treatment of refractory and relapsed B lymphocyte leukemia. However, several challenges and difficulties remain on the way to reach generic and effective T cell immunotherapy, including lacking a generic method for generating anti-leukemia-specific T cells from every patient. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S20459769183001
Publisher Site
http://dx.doi.org/10.1016/j.cr.2018.09.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6326242PMC
December 2018
10 Reads

The potential health gain and cost savings of improving adherence in chronic myeloid leukemia.

Leuk Lymphoma 2019 Jan 22:1-8. Epub 2019 Jan 22.

a Department of Hematology , Radboud University Medical Center , Nijmegen , T he Netherlands.

Healthcare costs are rising due to an increase in chronic diseases, including chronic myeloid leukemia (CML) due to improved survival. In CML care, patient adherence and physician adherence are key elements. We assessed the potential health gain and cost savings when both are improved, using a decision analytic model that integrated various sources of evidence. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2018.1535113DOI Listing
January 2019
1 Read

Detection of fusion gene transcripts in the saliva of Nigerian patients with chronic myeloid leukemia.

Niger J Clin Pract 2019 Jan;22(1):51-55

Department of Medical Laboratory Sciences, Faculty of Health Sciences and Technology, University of Nigeria, Enugu, Nigeria.

Background: The presence of BCR-ABL1 fusion gene resulting from a t(9; 22) reciprocal chromosome translocation is the molecular hallmark of chronic myeloid leukemia (CML). In the diagnosis and treatment of CML, peripheral blood or bone marrow samples are usually taken for analysis. However, both methods are invasive sample collection methods, thus a noninvasive saliva sample method for the detection of the fusion gene transcripts (BCR-ABL) was investigated in some Nigerians with CML. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/njcp.njcp_225_18DOI Listing
January 2019
2 Reads

Isolation of anticancer and anti-trypanosome secondary metabolites from the endophytic fungus Aspergillus flocculus via bioactivity guided isolation and MS based metabolomics.

J Chromatogr B Analyt Technol Biomed Life Sci 2019 Feb 6;1106-1107:71-83. Epub 2019 Jan 6.

Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 0RE, UK. Electronic address:

This study aims to identify bioactive anticancer and anti-trypanosome secondary metabolites from the fermentation culture of Aspergillus flocculus endophyte assisted by modern metabolomics technologies. The endophyte was isolated from the stem of the medicinal plant Markhamia platycalyx and identified using phylogenetics. Principle component analysis was employed to screen for the optimum growth endophyte culturing conditions and revealing that the 30-days rice culture (RC-30d) provided the highest levels of the bioactive agents. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jchromb.2018.12.032DOI Listing
February 2019
11 Reads

Bone mesenchymal stromal cells exhibit functional inhibition but no chromosomal aberrations in chronic myelogenous leukemia.

Oncol Lett 2019 Jan 9;17(1):999-1007. Epub 2018 Nov 9.

Central Laboratory, Fujian Provincial Key Laboratory of Hematology, Fujian Medical University Union Hospital, Fuzhou, Fujian 350001, P.R. China.

Chronic myelogenous leukemia (CML) is a myeloproliferative neoplasia characterized by the presence of the Philadelphia (Ph) chromosome in hematopoietic cells (HCs). As one of the most important components of the bone marrow microenvironment (BMM), bone mesenchymal stromal cells (BMSCs) are critical in the development of leukemia and essential in the regulation of hematopoiesis. However, little is known regarding the alterations of BMSCs in CML. Read More

View Article

Download full-text PDF

Source
http://www.spandidos-publications.com/10.3892/ol.2018.9681
Publisher Site
http://dx.doi.org/10.3892/ol.2018.9681DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6312938PMC
January 2019
7 Reads

Albumin binding and anticancer effect of magnesium oxide nanoparticles.

Int J Nanomedicine 2019 27;14:257-270. Epub 2018 Dec 27.

Department of Nanotechnology, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran,

Background: Recently, nanomaterials have moved into biological and medicinal implementations like cancer therapy. Therefore, before clinical trials, their binding to plasma proteins like human serum albumin (HSA) and their cytotoxic effects against normal and cancer cell lines should be addressed.

Methods: Herein, the interaction of magnesium oxide nanoparticles (MgO NPs) with HSA was studied by means of fluorescence spectroscopy, circular dichroism (CD) spectroscopy, and docking studies. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/albumin-binding-and-anticancer-eff
Publisher Site
http://dx.doi.org/10.2147/IJN.S186428DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6312066PMC
February 2019
10 Reads

In vitro activity of resorcinarene-chlorambucil conjugates for therapy in human chronic myelogenous leukemia cells.

Drug Dev Ind Pharm 2019 Apr 28;45(4):683-688. Epub 2019 Jan 28.

a a Departament of Química Orgánica , Instituto de Química, Universidad Nacional Autónoma de México , Ciudad de México , Mexico.

A possible way of improving the activity and selectivity profile of antitumor agents is to design drug carrier systems employing soluble macromolecules. Thus, four resorcinarene-PAMAM-dendrimer conjugates of chlorambucil with different groups in the lower part of the macrocycle and different length dendritic arms showed a good stability of the chemical link between drug and spacer. Evaluation of the cytotoxicity of the resorcinarene-PAMAM-dendrimer-chlorambucil conjugate employing a sulforhodamine B (SRB) assay in K-562 (human chronic myelogenous leukemia cells) demonstrated that the conjugate was more potent as an antiproliferative agent than chlorambucil. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/03639045.2019.1569036DOI Listing
April 2019
4 Reads

Persistence with generic imatinib for chronic myeloid leukemia: a matched cohort study.

Haematologica 2019 Jan 10. Epub 2019 Jan 10.

Jewish General Hospital and McGill University, Montreal, QC, Canada;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.211235DOI Listing
January 2019
3 Reads

Ponatinib-induced cardiotoxicity: delineating the signaling mechanisms and potential rescue strategies.

Cardiovasc Res 2019 Jan 10. Epub 2019 Jan 10.

Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.

Aims: Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of chronic myelogenous leukemia (CML). However, cardiotoxicity of these agents remains a serious concern. The underlying mechanism of these adverse cardiac effects is largely unknown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/cvr/cvz006DOI Listing
January 2019
2 Reads

The concomitant use of tyrosine kinase inhibitors and proton pump inhibitors: Prevalence, predictors, and impact on survival and discontinuation of therapy in older adults with cancer.

Cancer 2019 Apr 3;125(7):1155-1162. Epub 2019 Jan 3.

Department of Pharmaceutical Health Outcomes and Policy, University of Houston, Houston, Texas.

Background: The concomitant use of tyrosine kinase inhibitors (TKIs) and proton pump inhibitors (PPIs) is a significant concern because of potential drug-drug interaction that reduces TKI absorption, thus potentially reducing the effectiveness of TKIs. The objective of this study was to evaluate the prevalence and predictors of concomitant TKI-PPI receipt and its impact on survival and therapy discontinuation in older adults with cancer.

Methods: This retrospective study used linked Surveillance, Epidemiology, and End Results-Medicare data for the years 2007 through 2012. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.31917DOI Listing
April 2019
4 Reads

A Case of Chronic Myelogenous Leukemia Occurring in a Patient Treated for Essential Thrombocythemia.

Am J Case Rep 2019 Jan 3;20:10-14. Epub 2019 Jan 3.

Department of Hematology and Medical Oncology, Emory University, Atlanta, GA, USA.

BACKGROUND Essential thrombocythemia (ET) is one of the BCR-ABL gene fusion negative chronic myeloproliferative disorders (MPDs), which also include polycythemia vera (PV), and myelofibrosis. Few clinical cases have reported the progression of ET to chronic myelogenous leukemia (CML) with the expression of the BCR-ABL gene. This report describes such a case and includes a review of other reported cases of CML co-occurring with BCR-ABL-negative chronic MPDs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12659/AJCR.911854DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6325661PMC
January 2019
2 Reads

Analysis of four types of leukemia using Gene Ontology term and Kyoto Encyclopedia of Genes and Genomes pathway enrichment scores.

Comb Chem High Throughput Screen 2018 Dec 31. Epub 2018 Dec 31.

School of Life Sciences, Shanghai University, 99 Shangda Road, Shanghai 200444. China.

Aim And Objective: Leukemia is the second common blood cancer after lymphoma, and its incidence rate has an increasing trend in recent years. Leukemia can be classified into four types: acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and chronic myelogenous leukemia (CML). More than forty drugs are applicable for different types of leukemia based on the discrepant pathogenesis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1386207322666181231151900DOI Listing
December 2018
2 Reads

Vitamin Е activates expression of С/EBP alpha transcription factor and G-CSF receptor in leukemic K562 cells.

Exp Oncol 2018 Dec;40(4):328-331

Institute of Molecular Biology and Genetics, NAS of Ukraine, Kyiv 03680, Ukraine.

Background: Chronic myeloid leukemia (CML) is a clonal hematopoietic stem cell disorder associated with the activity of BCR-ABL fusion oncogene. Tyrosine kinase inhibitors are the current treatment of CML, but secondary mutations finally contribute to therapy resistance and blast crisis of the disease. The search for the novel compounds for the effective control of CML is now in the spotlight. Read More

View Article

Download full-text PDF

Source
December 2018
8 Reads

B-ALL Relapses After Autologous Stem Cell Transplantation Associated With a Shift from e1a2 to e14a2 Transcripts: A Case Report.

Anticancer Res 2019 Jan;39(1):431-435

Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.

Background/aim: The Philadelphia chromosome is found in 30% of acute lymphoblastic leukemia (ALL) patients, a distinct ALL subgroup where the BCR-ABL fusion gene is associated with poor prognosis. Treatment with tyrosine kinase inhibitors (TKIs) often induces complete remission and these patients subsequently undergo an autologous stem cell transplantation (ASCT). However, 20% of subjects experience a relapse associated with the selection of point-mutations in the BCR-ABL kinase domain. Read More

View Article

Download full-text PDF

Source
http://ar.iiarjournals.org/lookup/doi/10.21873/anticanres.13
Publisher Site
http://dx.doi.org/10.21873/anticanres.13130DOI Listing
January 2019
22 Reads

Chloroquine Inhibits Self-Renewal of Blast Progenitors Synergistically With Phytochemicals or Nonsteroidal Anti-inflammatory Drugs in Hematological Malignant Cell Lines.

Anticancer Res 2019 Jan;39(1):87-98

Department of Hematology, Center for University-Wide Education, School of Health and Social Services, Saitama Prefectural University, Saitama, Japan

Background: This study examined whether and how chloroquine inhibits blast progenitor self-renewal (SR) synergistically with phytochemicals or nonsteroidal anti-inflammatory drugs in seven hematological malignant cell lines.

Materials And Methods: Vitamin C, resveratrol, cyclo-oxygenase inhibitor NS-398 and indomethacin heptyl ester (Ind) were added to cell culture with or without 3 μM chloroquine.

Results: Chloroquine synergistically inhibited blast colony formation in methylcellulose with vitamin C, resveratrol, NS-398 and Ind in one, two, none and one cell lines, respectively, in a total of four out of 28 conditions. Read More

View Article

Download full-text PDF

Source
http://ar.iiarjournals.org/lookup/doi/10.21873/anticanres.13
Publisher Site
http://dx.doi.org/10.21873/anticanres.13083DOI Listing
January 2019
9 Reads

Assessment of soluble cytotoxic T lymphocyte-associated antigen-4, transforming growth factor β, and platelet-derived microparticles during dasatinib therapy for patients with chronic myelogenous leukemia.

J Blood Med 2019 19;10:1-8. Epub 2018 Dec 19.

First Department of Internal Medicine, Kansai Medical University, Hirakata, Osaka, Japan,

Background: The outcome for chronic myelogenous leukemia (CML) patients presented in the chronic phase has changed dramatically since the introduction of tyrosine kinase inhibitor (TKI) therapy. Notably, an increased incidence of large granular lymphocytes (LGLs), which is related to immunological conditions, appears to be predictive of a favorable outcome for dasatinib therapy. We therefore examined the immunological characteristics of CML patients during dasatinib therapy by determining the plasma concentrations of five different biomarkers. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/assessment-of-soluble-cytotoxic-t-
Publisher Site
http://dx.doi.org/10.2147/JBM.S187005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6305157PMC
December 2018
8 Reads

Post-treatment de-phosphorylation of p53 correlates with dasatinib responsiveness in malignant melanoma.

BMC Cell Biol 2018 12 27;19(1):28. Epub 2018 Dec 27.

Department of Physiology & Medical Physics, Royal College of Surgeons in Ireland, Dublin 2, Ireland.

Background: Dasatinib (Sprycel) was developed as a tyrosine kinase inhibitor targeting Bcr-Abl and the family of Src kinases. Dasatinib is commonly used for the treatment of acute lymphoblastic and chronic myelogenous leukemia. Previous clinical studies in melanoma returned inconclusive results and suggested that patients respond highly heterogeneously to dasatinib as single agent or in combination with standard-of-care chemotherapeutic dacarbazine. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12860-018-0180-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6307246PMC
December 2018
11 Reads